Received Jun 30, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (MODERNA)) | MODERNA | UNK | — | IM |
| COVID19 | COVID19 (COVID19 (UNKNOWN)) | UNKNOWN MANUFACTURER | UNK | — | — |
flu like symptoms; malaise; illness; high fever; This spontaneous case was reported by a consumer and describes the occurrence of INFLUENZA LIKE ILLNESS (flu like symptoms), MALAISE (malaise), ILLNESS (illness) and PYREXIA (high fever) in a 43-year-old female patient who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis. Co-suspect product included non-company product COVID-19 vaccine prot. subunit (NVX CoV 2373) (Novavax COVID-19 Vaccine) for an unknown indication. Concurrent medical conditions included Immunocompromised. On an unknown date, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (Intramuscular use) 1 dosage form and dose of COVID-19 vaccine prot. subunit (NVX CoV 2373) (Novavax COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced INFLUENZA LIKE ILLNESS (flu like symptoms), MALAISE (malaise), ILLNESS (illness) and PYREXIA (high fever). At the time of the report, INFLUENZA LIKE ILLNESS (flu like symptoms), MALAISE (malaise), ILLNESS (illness) and PYREXIA (high fever) had resolved. The action taken with mRNA-1273.815 (SPIKEVAX 2023-2024) (Intramuscular use) was unknown. No concomitant medications were reported. The patient experienced flu-like symptoms and fever following every COVID-19 vaccine received (both Moderna and Novavax). Reported fever after second Novavax dose. Reactions including high fever, malaise, and illness lasting 24-48 hours. Despite the side effects, the patient continued vaccination due to immunocompromised status. It was unknown if the patient experienced any additional symptoms/events. No treatment information was provided.
Immunocompromised